![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Neurolief Gets Breakthrough Designation for Depression Neuromodulator
Neurolief Gets Breakthrough Designation for Depression Neuromodulator
![](https://www.fdanews.com/ext/resources/test/Device_Images6/Neurolief_Logo.gif?t=1562712102&width=430)
Neurolief has received a Breakthrough designation from the FDA for its Relivion DP system, a wearable neuromodulator for the treatment of major depressive disorder (MDD).
The non-invasive device is designed to be used in combination with drugs to treat the disorder in adults who have not adequately responded to pharmaceuticals alone.
In a clinical trial, ninety percent of MDD patients who did not adequately respond to a pharmaceutical treatment showed improvement when using the device, and 37 percent of patients achieved full remission from their depressive episodes, the company said.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct